Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease

Published:2020-08-25 Issue: Volume: Page:
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chupin Antoine¹^ORCID,Perduca Vittorio²^ORCID,Meyer Antoine¹^ORCID,Bellanger Christophe¹,Carbonnel Franck¹,Dong Catherine¹^ORCID

Affiliation:

1. Department of Gastroenterology; Hôpital de Bicêtre; Assistance Publique-Hôpitaux de Paris and Université Paris Saclay; Le Kremlin-Bicêtre France

2. Université de Paris, CNRS, MAP5 UMR 8145; Paris France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.16050/fullpdf

Reference40 articles.

1. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review;Molodecky;Gastroenterology,2012

2. Targeting TNF-α for the treatment of inflammatory bowel disease;Billiet;Expert Opin Biol Ther,2014

3. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

4. Drug safety evaluation of certolizumab pegol;Ferrante;Expert Opin Drug Saf,2014

5. Safety considerations when using anti-TNFα therapy to treat Crohn's disease;Pagnini;Expert Opin Drug Saf,2015

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis;Pharmaceuticals;2024-08-05

3. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21

4. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment;Journal of Crohn's and Colitis;2024-06-15

5. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19